Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.56 USD
+0.02 (0.59%)
Updated Aug 8, 2024 10:00 AM ET
After-Market: $2.61 +0.05 (1.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARMP 2.56 +0.02(0.59%)
Will ARMP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARMP
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Other News for ARMP
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Armata Pharmaceuticals receives $5.25M of funding from DoD
Armata Pharmaceuticals Updates Chief Medical Officer’s Compensation
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024